171 related articles for article (PubMed ID: 38271655)
61. Selpercatinib in Patients With
Drilon A; Subbiah V; Gautschi O; Tomasini P; de Braud F; Solomon BJ; Shao-Weng Tan D; Alonso G; Wolf J; Park K; Goto K; Soldatenkova V; Szymczak S; Barker SS; Puri T; Bence Lin A; Loong H; Besse B
J Clin Oncol; 2023 Jan; 41(2):385-394. PubMed ID: 36122315
[TBL] [Abstract][Full Text] [Related]
62. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
63. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
64. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
Zhou Q; Zhao J; Chang J; Wang H; Fan Y; Wang K; Wu G; Nian W; Sun Y; Sun M; Wang X; Shi H; Zheng X; Yao S; Qin M; Shen Z; Yang J; Wu YL
Cancer; 2023 Oct; 129(20):3239-3251. PubMed ID: 37282666
[TBL] [Abstract][Full Text] [Related]
67. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
68. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
69. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
Wright KM
Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
[TBL] [Abstract][Full Text] [Related]
70. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
71. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
72. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
Velcheti V; Madison R; Ali SM; Schrock AB
J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
[No Abstract] [Full Text] [Related]
73. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
[TBL] [Abstract][Full Text] [Related]
74. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
75. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
76. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
[TBL] [Abstract][Full Text] [Related]
77. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract][Full Text] [Related]
78. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
79. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
80. A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
Xu X; Wang H; Yu Z; Chen X
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1825-1827. PubMed ID: 35364706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
